Baudax Bio Reports First Quarter Financial Results and Provides Business Update
12 mai 2023 08h32 HE
|
Baudax Bio, Inc.
Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent...
Baudax Bio to Present at the Sidoti Virtual Investor Conference
03 mai 2023 16h05 HE
|
Baudax Bio, Inc.
MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today...
Baudax Bio Announces Closing of $4 Million Public Offering
01 mai 2023 17h43 HE
|
Baudax Bio, Inc.
MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related...
Baudax Bio Announces Pricing of $4 Million Public Offering
26 avr. 2023 21h15 HE
|
Baudax Bio, Inc.
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related...
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
25 avr. 2023 08h00 HE
|
Baudax Bio, Inc.
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions at 60 Seconds Results to be Discussed in Key Opinion Leader Webinar Today at 10:00am Eastern...
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
24 avr. 2023 16h30 HE
|
Baudax Bio, Inc.
MALVERN, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today...
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
27 mars 2023 08h00 HE
|
Baudax Bio, Inc.
41 Subjects Meet Criteria for Good or Excellent Intubation Conditions at 60 Seconds Top Line Results Expected Late April/Early May MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Baudax Bio,...
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
23 févr. 2023 08h00 HE
|
Baudax Bio, Inc.
Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1...
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
24 janv. 2023 08h00 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the...
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
08 déc. 2022 08h00 HE
|
Baudax Bio, Inc.
MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the...